Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 104.04% | 100.93% | 60.80% | 37.94% | 22.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.04% | 100.93% | 60.80% | 37.94% | 22.22% |
| Cost of Revenue | 57.57% | -33.00% | -19.89% | -49.68% | -52.18% |
| Gross Profit | 106.55% | 114.06% | 68.40% | 48.97% | 33.46% |
| SG&A Expenses | 22.64% | 23.23% | 22.09% | 21.60% | 23.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.01% | -4.93% | -4.41% | -4.92% | -0.80% |
| Operating Income | 56.39% | 48.03% | 32.36% | 20.69% | 9.53% |
| Income Before Tax | 86.98% | 76.95% | 62.84% | 50.02% | 8.38% |
| Income Tax Expenses | 26.76% | -68.30% | -79.48% | -88.73% | -81.51% |
| Earnings from Continuing Operations | 86.77% | 76.92% | 62.92% | 50.39% | 9.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.77% | 76.92% | 62.92% | 50.39% | 9.06% |
| EBIT | 56.39% | 48.03% | 32.36% | 20.69% | 9.53% |
| EBITDA | 58.75% | 48.98% | 32.77% | 21.03% | 9.73% |
| EPS Basic | 87.80% | 77.64% | 63.45% | 50.87% | 10.38% |
| Normalized Basic EPS | 51.54% | 43.89% | 29.66% | 18.34% | 6.77% |
| EPS Diluted | 87.18% | 77.08% | 62.89% | 50.39% | 10.40% |
| Normalized Diluted EPS | 52.09% | 44.41% | 30.18% | 18.83% | 6.77% |
| Average Basic Shares Outstanding | 3.80% | 3.11% | 2.39% | 1.80% | 1.53% |
| Average Diluted Shares Outstanding | 4.71% | 4.03% | 3.31% | 2.72% | 1.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |